Form 4: MannKind CFO Awarded Performance RSUs & Stock Options

MannKind's Chief Financial Officer, Christopher B. Prentiss, was granted 221,000 performance-based restricted stock units and 217,000 employee stock options on March 23, 2026.

Summary

• Christopher B. Prentiss, Chief Financial Officer of MannKind Corp (MNKD), received an award of 221,000 Performance Restricted Stock Units (RSUs) on March 23, 2026.
• Each RSU represents a contingent right to receive one share of MNKD common stock.
• The performance RSUs will vest on January 15, 2029, with the number of shares delivered determined by MannKind's Total Shareholder Return (TSR) relative to the Russell 3000 Pharmaceutical & Biotechnology Index over the period from April 1, 2026, to December 31, 2028.
• Payout for the performance RSUs ranges from 0% of target (less than 25th percentile TSR) to 300% of target (90th percentile or higher TSR), with interpolation for intermediate rankings.
• Prentiss also received an award of 217,000 Employee Stock Options on March 23, 2026, with an exercise price of $2.44 per share.
• These stock options begin vesting 25% on March 23, 2027, and thereafter 1/16th quarterly, with an expiration date of March 23, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices designed to align management incentives with long-term shareholder value, without indicating any immediate operational or financial changes.

Positives

• The equity grants align the Chief Financial Officer's long-term interests with those of shareholders, incentivizing strong company performance.
• Performance-based RSUs tie a significant portion of executive compensation directly to MannKind's total shareholder return relative to an industry benchmark, promoting competitive performance.

Negatives

• The issuance of new shares upon vesting and exercise of these awards could lead to future dilution for existing shareholders.

Risks

• The performance-based restricted stock units carry the risk that MannKind's Total Shareholder Return (TSR) may not meet the specified percentile rankings relative to the Russell 3000 Pharmaceutical & Biotechnology Index, potentially resulting in a lower or zero payout.
• The value of the employee stock options is subject to the future market price of MannKind's common stock, and if the stock price does not exceed the exercise price of $2.44, the options may expire worthless.

Future Outlook

The future payout of the performance-based restricted stock units is contingent on MannKind's Total Shareholder Return (TSR) performance relative to the Russell 3000 Pharmaceutical & Biotechnology Index between April 1, 2026, and December 31, 2028. The employee stock options will vest incrementally starting March 23, 2027, and expire on March 23, 2036.

Industry Context

StockSavvy.ai notes that the granting of performance-based restricted stock units and stock options is a common practice in the biotechnology and pharmaceutical industries. This compensation structure is designed to attract and retain executive talent while aligning their incentives with long-term shareholder value creation, particularly through metrics like Total Shareholder Return (TSR) relative to industry peers.

Comparison to Industry Standards

• The use of performance-based restricted stock units tied to relative TSR is a standard practice among publicly traded companies, particularly in sectors like biotechnology, to ensure executive compensation is directly linked to market-relative performance.
• Stock options with multi-year vesting schedules and a 10-year term are also typical forms of long-term incentive compensation in the industry, comparable to practices at companies such as Amgen, Gilead Sciences, or Biogen, which frequently utilize similar equity-based awards for their executives.

Stakeholder Impact

• Shareholders: Potential for long-term value creation if the compensation structure effectively incentivizes strong performance, balanced against potential future dilution from the issuance of new shares upon vesting and exercise.
• Employees: The compensation structure for a key executive may set a precedent or reflect the company's overall approach to performance-based incentives.

Next Steps

• MannKind's Total Shareholder Return (TSR) will be measured against the Russell 3000 Pharmaceutical & Biotechnology Index from April 1, 2026, to December 31, 2028, to determine the payout of the performance RSUs.
• The performance RSUs are scheduled to vest on January 15, 2029.
• The employee stock options will begin vesting 25% on March 23, 2027, with subsequent quarterly vesting.

Key Dates

Keywords

MannKind Corp, MNKD, SEC Form 4, Insider Transaction, Executive Compensation, Restricted Stock Units, Stock Options, Performance-based compensation, Chief Financial Officer, Equity Grant, TSR, Russell 3000 Pharmaceutical & Biotechnology Index